GO:0006148 inosine catabolic process explained

GO:0006148, inosine catabolic process, is the set of chemical reactions and pathways that result in the breakdown of inosine, the hypoxanthine riboside nucleoside. Inosine is unusual among nucleosides because it is found free in cells and is not a standard constituent of nucleic acids, except at the anticodons of some tRNAs where it is generated post-transcriptionally by adenosine-to-inosine (A-to-I) editing. Because inosine sits at the intersection of purine salvage, RNA modification and extracellular signaling, its catabolism is relevant to basic metabolism and to disease. The term is defined in QuickGO as the chemical reactions and pathways resulting in the breakdown of inosine, hypoxanthine riboside, a nucleoside found free but not in combination in nucleic acids except in the anticodons of some tRNAs. In practice, inosine catabolism supplies hypoxanthine for purine salvage or for further oxidation to uric acid, and it can be coupled to nucleoside phosphorylase and deaminase activities that interconvert purine nucleosides. A-to-I editing by ADAR enzymes generates inosine within RNA, and the downstream handling of edited inosine connects this catabolic process to the broader biology of RNA editing. For researchers, GO:0006148 matters because inosine is both a metabolite and a signaling molecule. Apoptotic brown adipocytes release extracellular inosine that enhances energy expenditure in neighboring cells, demonstrating a physiological role for inosine and its metabolic handling. In parallel, A-to-I editing and inosine metabolism influence hematopoiesis and cancer biology, so tools that manipulate inosine catabolic genes are increasingly used to dissect these pathways. This article summarizes the definition, mechanism, key genes, disease links and experimental methods for studying inosine catabolic process.

Inosine catabolic process (GO:0006148) is the biological process in which the nucleoside inosine is enzymatically broken down into smaller purine metabolites. Inosine is a hypoxanthine riboside that occurs free in cells and is not a normal building block of nucleic acids, except in the anticodons of some tRNAs where it arises from adenosine-to-inosine editing. Catabolism of inosine typically involves phosphorolytic cleavage to hypoxanthine and ribose-1-phosphate, and hypoxanthine can then enter salvage or oxidative pathways. The process is therefore a metabolic hub connecting RNA editing, purine salvage and extracellular purine signaling.

Inosine catabolic process is important because inosine is a metabolic and signaling node rather than a passive degradation product. Inosine is generated in RNA by A-to-I editing and is also present as a free nucleoside, and its catabolism determines whether purine carbon and nitrogen are salvaged or oxidized. The discovery that apoptotic brown adipocytes release extracellular inosine to enhance energy expenditure shows that inosine handling has systemic physiological consequences. In disease, altered A-to-I editing and inosine metabolism are linked to cancer and hematopoietic disorders, so understanding GO:0006148 supports mechanistic studies and therapeutic hypothesis generation.

The following genes and proteins are experimentally and conceptually linked to inosine catabolic process, inosine generation by RNA editing, and inosine signaling.

Inosine catabolic process is regulated at multiple levels. The availability of inosine depends on A-to-I editing by ADAR enzymes, which determines how much edited inosine is generated in RNA. Transport of inosine across membranes controls its access to intracellular catabolic enzymes and its extracellular signaling actions, as shown for inosine released by apoptotic brown adipocytes. Purine salvage and oxidation enzymes set the metabolic fate of hypoxanthine produced by inosine breakdown. In disease contexts such as cancer and hematopoiesis, A-to-I editing and inosine-related pathways are dynamically regulated, providing additional layers of control.

A-to-I RNA editing and inosine metabolism are increasingly recognized as contributors to cancer biology. Because ADAR enzymes generate inosine in transcripts, altered editing can change RNA function and downstream metabolic handling of inosine. Recent advances in A-to-I editing in cancer highlight opportunities to target editing and inosine-related pathways for therapeutic hypothesis testing. Inosine catabolic process is therefore relevant to understanding how edited transcripts and purine metabolites influence tumor cell behavior.

A-to-I RNA editing and hematopoiesis are mechanistically linked, and inosine is the edited base produced by ADAR enzymes. This connection places inosine catabolic process in the context of blood cell development and hematopoietic disease. Dysregulated editing can affect transcript fate and cellular metabolism, with implications for hematopoietic differentiation. Studying inosine catabolism in hematopoietic models may clarify how purine metabolism intersects with blood cell biology.

Extracellular inosine released from apoptotic brown adipocytes enhances energy expenditure, demonstrating a role for inosine in systemic metabolism. Inosine and related purines also participate in inflammatory and redox signaling relevant to human disease. Because catabolism terminates inosine signaling and generates hypoxanthine, the balance between inosine production, transport and breakdown can influence metabolic and inflammatory outcomes. These findings support investigating inosine catabolic genes in metabolic and inflammatory disease models.

Because inosine in RNA arises from A-to-I editing, transcriptome-wide editing detection is a primary method for studying the upstream source of inosine. Single-cell RNA editing profiling extends this to heterogeneous cell populations and can reveal cell-state-specific editing activity. These approaches connect ADAR activity to the inosine substrate pool relevant to GO:0006148.

Measuring inosine, hypoxanthine and related purine metabolites provides direct evidence of catabolic activity. Stable-isotope tracing can follow purine carbon and nitrogen through salvage and oxidation routes. Such metabolite profiling is essential for linking candidate genes to the catabolic process defined by GO:0006148.

Extracellular inosine signaling can be assayed by treating cells with inosine and measuring metabolic or inflammatory readouts. Apoptotic brown adipocyte models have been used to show that released inosine enhances energy expenditure. Combining such assays with transporter or catabolic enzyme perturbations tests the role of inosine handling in signaling.

CRISPR knockout, point mutation, knock-in and overexpression enable causal tests of inosine catabolic genes. Library screening can nominate genes that modify inosine-related phenotypes in disease-relevant cells. Bioinformatics integration of editing, expression and metabolite data helps prioritize candidates for follow-up.

Researchers studying inosine catabolic process-related genes often need to determine whether a candidate gene is causally involved in inosine breakdown, RNA editing or downstream signaling. EDITGENE provides publication-ready CRISPR cell models and bioinformatics support to move from correlation to mechanism.

GO:0006148 inosine catabolic process defines the breakdown of inosine, a nucleoside that is both a product of A-to-I RNA editing and an extracellular signaling molecule. Its study connects purine metabolism, epitranscriptomics and disease biology, with implications for cancer, hematopoiesis and metabolic physiology. CRISPR-based models and editing-aware bioinformatics provide practical routes to test causal roles of inosine pathway genes. EDITGENE supports these efforts with knockout, point-mutation, knock-in, overexpression and screening services tailored to inosine catabolic process research.